FDA Support for Developing Products for Rare Diseases & Conditions

The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.  In fulfilling that task, OOPD evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. The office also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.Continue reading

Critical Path Institute names Martha Brumfield CEO

The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interim president and chief executive officer of the organization. Brumfield, C-Path’s former director of International & Regulatory Programs, takes over immediately for Carolyn Compton, M.D., Ph.D., who will be assuming a new position at Arizona State University (ASU).Continue reading

Tucson ScienceWorks: Sparking a love for science in future innovators

The impact of science and technology on our lives grows with each passing day. Yet, with so much continually swirling around us, the basic workings of the world we live in have become obscured, its simple beauty hidden.  It’s not that we have given up on being curious. It’s just that for many of us, the world we face seems too complex to understand.Continue reading